Home > Compound List > Product Information
N-Methyl-4-piperidinol_Molecular_structure_CAS_106-52-5)
Click picture or here to close

N-Methyl-4-piperidinol

Catalog No. H42206 Name Sigma Aldrich
CAS Number 106-52-5 Website http://www.sigmaaldrich.com
M. F. C6H13NO Telephone 1-800-521-8956
M. W. 115.17352 Fax
Purity 98% Email
Storage Chembase ID: 91299

SYNONYMS

Title
N-甲基-4-哌啶醇
IUPAC name
1-methylpiperidin-4-ol
IUPAC Traditional name
4-piperidinol, 1-methyl-
Synonyms
1-Methyl-4-piperidinol
4-Hydroxy-1-methylpiperidine
1-甲基-4-哌啶醇
4-羟基-1-甲基哌啶

DATABASE IDS

PubChem SID 24895629
CAS Number 106-52-5
EC Number 203-406-8
MDL Number MFCD00006500
Beilstein Number 103024

PROPERTIES

Empirical Formula (Hill Notation) C6H13NO
Purity 98%
Boiling Point 200 °C(lit.)
Flash Point 112 °C
Flash Point 233.6 °F
Melting Point 29-31 °C(lit.)
Refractive Index n20/D 1.4775(lit.)
GHS Pictograms GHS05
GHS Pictograms GHS07
GHS Signal Word Danger
GHS Hazard statements H315-H318-H335
European Hazard Symbols Irritant Irritant (Xi)
MSDS Link Download
Personal Protective Equipment Eyeshields, full-face respirator (US), Gloves, multi-purpose combination respirator cartridge (US), type ABEK (EN14387) respirator filter
GHS Precautionary statements P261-P280-P305 + P351 + P338
Risk Statements 37/38-41
Safety Statements 26-37/39
Storage Temperature 2-8°C
German water hazard class 3

DETAILS

Description (English)
Packaging
100 g in glass bottle
Application
Reactant for:
• Optimization of Novobiocin scaffold to product antitumor agents1
• Substitution about the rigidifying ring for histamine H4 receptor antagonist synthesis2Reactant for synthesis of:
• CaMKII inhibitors3
• VEGFR and FGFR kinase inhibitors4
• Phosphoinositide-3-kinase inhibitors5
• Protein lysine methyltransferase G9a inhibitors6
Description (简体中文)
包装
100 g in glass bottle
Application
Reactant for:
• Optimization of Novobiocin scaffold to product antitumor agents1
• Substitution about the rigidifying ring for histamine H4 receptor antagonist synthesis2Reactant for synthesis of:
• CaMKII inhibitors3
• VEGFR and FGFR kinase inhibitors4
• Phosphoinositide-3-kinase inhibitors5
• Protein lysine methyltransferase G9a inhibitors6

REFERENCES